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Abstract
Background: Nocebo effects (‘negative placebo’ effects) experienced by clinical trial participants can arise from an
underlying condition or through communication about side effects in the participant information leaflets (or
elsewhere). Misattributing nocebo effects to the medicinal intervention can lead to participants experiencing
harmful nocebo effects and may result in distortion of adverse effect reporting. However, little is known about how
information on potential side effects is provided to trial participants. There is increasing concern that the way in
which potential side effects in clinical trials are described to patients in participant information leaflets (PIL) can in
itself cause harm by either increased anxiety, poor adherence or inducing the side effect itself. In this study, we
aimed to explore these concerns and identify the way in which potential side effects from investigational medicinal
products used in trials are presented in written information to potential participants.
Methods: Trials were identified from the International Standard Randomised Controlled Trials Number (ISRCTN)
clinical trial registry (a primary registry of the WHO International Clinical Trials Registry Platform (ICTRP)). Eligible
studies were placebo-controlled clinical trials of investigational medicinal products (IMP) in adults conducted in the
UK. We assessed readability using the Flesch Reading Ease scale, Gunning-Fog Index and Flesch-Kincaid Grade. Data
extracted from the PILs were divided into 8 predefined qualitative themes for analysis in NVivo11.
Results: Most of the patient information leaflets were ranked as ‘fairly difficult to read’ or ‘difficult to read’
according to the Flesch Reading Ease scale. All studies presented information about adverse events, whereas only a
third presented information about intervention benefits. Where intervention or study benefits were presented, they
were usually after adverse events (21/33, 64%).
Discussion: Participant information leaflets scored poorly on ease of readability and had more content relating to
adverse effects than any potential beneficial effects. The way in which adverse events were presented was
heterogeneous in terms of their likelihood and severity and the amount and level of detail provided. By
comparison, potential benefits from the intervention and/or study were described less often, by shorter text, and
only after information about harms.
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Background
The placebo effect is well-documented in the literature
and occurs when patients experience an improvement in
their symptoms in response to an intervention which is
biologically inert with respect to their condition yet
which they believe is helpful [1]. The nocebo effect is
tantamount to the placebo effect but differs in that
nocebo effects arise from a belief that an adverse effect
occurs from the patient’s negative expectations [2]. This
negative expectation will come from a belief that the
drug that they are taking will do them harm. A recent
overview of systematic reviews (20 systematic reviews
which included 1271 trials across multiple disciplines)
found that 50% of trial participants who are allocated to
placebo groups experience adverse effects, and 5% drop
out of the trial due to ‘drug-induced’ intolerance [3].
The included reviews found that for primary headache
disorders the nocebo frequency was 18.67% [4] (56
trials—placebo participants not reported), in RCTs for
depression 44.70% (21 trials 3255 placebo participants)
[5], in neuropathic pain trials it was 52.0% (12 trials 943
placebo participants) [6], RCTs for pharmacologic treat-
ments for Parkinson’s 64.70% (41 trials 3544 placebo
participants) [7], and RCTs for fibromyalgia treatment
67.20% placebo-treated patients reported AEs (16 trials
2016 placebo participants) [8].
However, it is extremely rare [9] for adverse reactions
to be directly caused by placebos. There are two overlap-
ping explanations for how this might occur. First, a pa-
tient may have an underlying condition whose natural
history produces an event (such as a headache), then the
patient misattributes the event to the trial intervention
(in their case, a placebo). Second, having been warned
about side effects in the patient information leaflet (or
elsewhere), the patient may expect an adverse effect
(AE). This negative expectation could then produce the
event [10].
All clinical trials are expected to produce participant
information leaflets (PILs) to inform potential partici-
pants about the aims of the research, what will happen
to them if they decide to take part and what the risks,
side effects and benefits are of taking part in the re-
search [11]. Informing patients about any research they
participate in is required by the general ethical principle
that we must respect patient autonomy and this is
clearly stated in the Declaration of Helsinki and the
Nuremberg code. More specifically, the PILs are a re-
quirement of Good Clinical Practice (GCP) [12]. There
is some evidence, however, that methods for achieving
informed consent through the PIL can introduce
unnecessary side effects and may therefore violate the
ethical requirement to avoid unnecessary harm [13]. In
one multicentre randomised trial of aspirin or sulfinpy-
razone for treating unstable angina, due to differences in
individual hospital review processes, patients either re-
ceived or did not receive a statement outlining possible
gastrointestinal side effects. In two out of the three
centres, this resulted in a 6-fold increase (P < 0.001) in
the number of individuals withdrawing from the study
because of subjective, minor gastrointestinal symptoms
[14]. This suggests that PILs may prompt patients to
expect side effects (nocebo effects), which may cause
patients to experience the side effects described.
To date, there has been very little research on how
PILs present information about harms. Some recent
work exploring participants’ views about information
provision has shown that the two most important infor-
mational items in a PIL for participants are the possible
side effects of trial treatment and the possible disadvan-
tages and risks of taking part in a study. The least
important item is whether participants would receive
payments for taking part [15]. This shows a clear indica-
tion that participants in clinical trials are primarily con-
cerned about the safety information contained in PILs
and seek this information out first. The HRA guidance
around describing risk and adverse effects in PILs states
that ‘A fair and honest evaluation of the consequences of
research, including possible significant benefits and
harms and their relative likelihoods, must be described
to potential participants and that potential participants
must be given an honest assessment of the likelihood
that something might go wrong, and the consequent
level of harm that might be caused’ [11].
In this study, we aimed to increase the evidence base
in this area by identifying the way in which potential side
effects from investigational medicinal products used in
trials are presented in written information to potential
participants.
Methods
Design
Ongoing and recently completed (within 3 years) trials
were identified from the International Standard Rando-
mised Controlled Trials Number (ISRCTN) clinical trial
registry https://www.isrctn.com/. Eligible studies were
placebo-controlled clinical trials of investigational medi-
cinal products (IMP) in adults conducted in the UK.
Three clinical areas were targeted: cancer, musculoskel-
etal conditions and mental and behavioural disorders.
The clinical areas we chose were based on previous
evidence that nocebo effects seem likely to affect these
areas, namely, musculoskeletal disorders, mental and
behavioural disorders and cancer. We chose more than
one area in order to compare PILs provided in condi-
tions with contrasting features in terms of treatment
aims, types and duration of treatment involved, and
anticipated side effects. Eligibility was restricted to either
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current trials or those within years of completion to
reflect current practice.
Data collection
If the PIL was available on the ISCRTN website, then it
was downloaded directly from there. If not, we sent an
email to a member of the study team who was listed on
the ISCRTN website. An email template was set up ask-
ing the named individual for each study to provide the
study team with the PIL for the given study. Following
sending the original email, the named individual was
followed up a maximum of 2 times.
Details of eligible studies were extracted and entered
into an Excel spreadsheet. Studies and study documents
were allocated a unique reference number and anon-
ymised to remove any identifiable information. Study
documents were reviewed for content relating to the
intervention and placebo used in the trial. Data was then
extracted by three members of the research team (NK,
SB, VS) and entered into qualitative data analysis soft-
ware (NVivo 11).
We used the Flesch Reading Ease Scale, Gunning-Fog
Index and Flesch-Kincaid Grade [16] to assess the read-
ability of participant information contained in the PILs.
The Flesch Reading Ease Scale and Flesch-Kincaid Grade
are able to measure how easily people can understand a
piece of text. The Flesch Reading Ease Scale rates the
reading ease from 5th Grade to college graduate (The
UK equivalent for this is from year 7 to a university
graduate). The Flesch-Kincaid Grade rates reading ease
using US grade levels via a formula to obtain a reading
ease. The Gunning fox index estimates the years of for-
mal education a person needs to understand the text on
the first reading; this is given in US school years.
As well as the reading indexes, the data extracted was
divided into 8 themes which were predefined before data
collection began from the PIL. These are descriptions of
the intervention and placebo. Data was also extracted on
the adverse effects listed, the likelihood and severity of
these events, what to do in the event of these adverse ef-
fects taking place and the description of the beneficial
effects for both the intervention and the trial itself. The
total length of the PIL and length of the text that details
the risks and adverse effects was also described.
Data analysis
We reported descriptive statistics (mean, median, range
and interquartile range) to report the word length for
the reading scales and the total length of the document
for risks and adverse effects and its overall length. This
was completed by study type and overall. Readability
scores were calculated for each information leaflet in
order to assess the accessibility of the information pro-
vided to trial participants.
The documents were reviewed in order to ensure
familiarity with the text, and the content areas from the
study documents were extracted and input into qualita-
tive data analysis software (NVivo 11).
We used the method outlined in Bengtsson et al. [17]
to conduct our qualitative analysis. This involved of a
series of iterative steps, with the four main stages being
decontextualisation of the unit of analysis, recontextuali-
sation, categorisation and compilation. The meaning
unit (or coding or content unit) is defined as words,
sentences or paragraphs containing aspects related to
each other through their content and context.
During the decontextualisation stage, the meaning unit
(the words or sentences that are intended to convey an
item of information or instruction) were coded, similar to
open-coding [18] using a generated coding list. Those
identified a priori include any description of a side effect,
the likelihood (rarity) of a side effect occurring, the
severity of a side effect should it occur, and any advice or
instructions to the participant following the occurrence of
a side effect. The data was coded iteratively (an approach
which is widely used in qualitative content analysis and
which allows for changes as new information is discov-
ered), in discussion with the research team, to increase the
stability and reliability of the coding process.
During the recontextualisation stage, the meaning units
were re-read alongside the original data to ensure the con-
tent is adequately captured, with no extraneous ‘dross’ in-
cluded that is not relevant to the aim of the study [17].
The compilation stage drew on a manifest level of
analysis, which remained very close to the original text
to describe what was said using the visible and obvious
[14]. Given the anticipated depth of data contained in
these types of documents, a manifest analysis which
stays closer to the original meaning and context was
appropriate. The data has been summarised narratively
according to each theme and category.
Results
Descriptive results
The ISCRTN search found 65 studies which were
eligible (18 musculoskeletal, 22 Mental and Behaviour
disorders and 25 cancer). Only 2 PILs were available on
the website so therefore the authors (NK, VS, SB) con-
tacted the study teams to request that they provided
their study documentation. Responses were received
from 34 studies (52%), these were broken down by 11
musculoskeletal (61%), 13 mental and behaviour disor-
ders (59%) and 10 cancer (40%). All of these studies
were included in the final analysis (Table 1).
The Flesch Reading Ease Scale range across all three
clinical areas ranged from fairly easy to read and too dif-
ficult to read (Fig. 1). The mean and median scores were
interpreted as fairly difficult to read.
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The mean reading ease across all clinical areas indi-
cated that all clinical areas were classified as fairly diffi-
cult to read (Fig. 1). This indicates that readers overall
would need to have a reading age of a 10th–12th grade
which in the UK equates to a 16–18 years old.
The Flesch-Kincaid Grade minimum to maximum
across all three clinical areas were interpreted as average
to skilled reading level. The median and the mean inter-
pretation grades are both at the higher level of average
reading ability. This would show that they were not
accessible to the general population.
The mean reading grade across all three clinical areas
found that all clinical areas had a higher level than the
average grade.
The Gunning Fox index range across all three clin-
ical areas were interpreted in the range of high school
sophomore (year 11 in the UK) to college senior (2nd
year university in the UK). The median score and the
mean scores were interpreted as high school senior
reading age (year 13 in the UK).
The reading index mean by individual study type are
all interpreted as high school senior reading age (year 13
in the UK).
The total length of the cancer PILs was longer than
the information leaflet from the other two clinical areas
with a mean of 5434 words in comparison to a mean of
2927 in the musculoskeletal studies and 3289 in the
mental and behaviour disorder studies.
The length of information leaflets in terms of describ-
ing adverse effects and risk in the cancer studies were
longer than the other two clinical areas (Table 2). with a
mean of 616 words in comparison to a mean of 157
words in the musculoskeletal study and 304 in the men-
tal and behaviour disorder studies. This was also
reflected in the percentage of words for adverse effects
and risk in comparison to the overall mean.
Overall, 30 of the trials that were sampled were using
licenced medications (9 cancer, 11 mental and behav-
iour disorders and 10 musculoskeletal); however, only
14 of these (4 cancer, 6 mental and behaviour and 4
musculoskeletal) were using the medication in a way
that was used within licenced range of indications,
dosage and form.
Qualitative data analysis
Following the start of the study, the description of the
placebo was further divided into sub-themes looking at
what the placebo is and why the placebo is being used.
We also divided the potential benefits into potential
benefits of the study and the potential benefits of the
intervention.
Table 1 Readability scores
Readability Scale Minimum and maximum Median Mean 1st quartile range 3rd quartile range IQR
Flesch Reading Ease 44.6–70.9 56.3 57 54.3 61.5 7.2
Flesch-Kincaid Grade 7.4–12.4 10.15 10.1 9.225 10.8 1.575
Gunning Fox index 10.3–16.4 12.3 12.4 11.675 13.15 1.475
Fig. 1 Reading scales by clinical area
Kirby et al. Trials          (2020) 21:658 Page 4 of 8
Description of the intervention under investigation
Reflecting the range of studies included, the data de-
scribing the interventions were extremely heterogeneous.
The details varied from providing only the drug name
and class (e.g. antidepressant (Sertraline)) to extensive
descriptions of the intervention and what it is (or usually
is) used for, and what the evidence is to date. Interven-
tions in the study documents for cancer trials were
generally more extensive than those in the musculoskel-
etal or mental health groups of studies.
Description of ‘placebo’ and the nature of the placebo used
All the included studies involved a placebo intervention
as either a substance or a procedure. A small number of
the study documents did not provide any information
about the placebo used, or what a ‘placebo’ is (5/33,
15%). Where a description was provided of what a
placebo is, the majority used the term ‘dummy’ (13/28
46%) or described it as not containing an active ingredi-
ent (17/28, 61%), others described it as being an inactive
substance (2/28, 7%), or described its physical character-
isitics as ‘looking the same’ as the active intervention
(11/28, 39%) or not being ‘able to tell which is which’ (1/
28, 4%). The effective characteristics of the placebo were
described as having ‘no therapeutic properties’ or ‘no
anti-cancer action’ (3/28, 11%). Many included a com-
bination of terms, e.g. ‘A placebo is sometimes called a
dummy treatment - it looks the same as the actual treat-
ment but does not contain any of the active ingredients
and will have no effect on you.’ [ID 204]. Two studies
which involved a placebo comparator for a minor
surgery intervention described the injection as a ‘sham’
procedure, and another described it as an imitation
injection. There were only two study documents which
described the ingredients of the placebo, one of which
was a saline injection and the other a gelatine capsule.
Description of why a placebo is used
The majority of the documents did not provide informa-
tion about why a placebo was being used (19/33, 58%).
Of those that did, a number of different reasons were
given. Some described it as ensuring that the patient (6/
14, 43%) and/or their doctor (4/14, 29%) would not
know whether they had been given the active interven-
tion or not, thus allowing for comparison (3/14, 21%)
meaning that the effect of just the active intervention
can be measured (4/14, 29%). A small number explained
that this reduces bias (3/14, 21%) and means that effects
are known to be not just due to chance (1/14, 7%) and
makes the trial results more robust (3/14, 21%). Some
used a combination of more than one, e.g. ‘If patients
are randomised to placebo tablets rather than no active
therapy, the doctor and patients will not know which
treatment the patients are taking. There is therefore less
scope for bias and this makes the results of the trial
more robust.’ [ID 103].
Description of potential adverse effects
As with the intervention itself, the adverse effects data
are heterogeneous in nature, with some study docu-
ments containing an extensive bullet-pointed list of in
excess of 50 side effects [ID 102], whilst others con-
tained a single short sentence which may include those
considered most likely to occur, e.g. ‘The more common
side effects are fatigue, insomnia/abnormal dreams and
nausea.’ [ID 222] or a brief paragraph [e.g. ID205 and ID
207]. Some studies provided information about how the
potential adverse effects are known, e.g. ‘Based on re-
search studies and the experience of other people taking
[name of investigational medicinal product], some side-
effects can be expected.’ [ID 104]. One study document,
for the evaluation of a tea-based intervention, did not
contain any information about adverse events [ID 210].
Likelihood of adverse effects
‘Almost all of the documents contained information
about the likelihood of any adverse effects occurring
(30/33, 91%). The three studies which did not provide
this information were a medication reduction interven-
tion, a study which involved a single tendon injection,
and the tea-based intervention study.’ Of those that did
report the likelihood, they were divided between those
that used a text description only (16/31, 52%) such as
‘rarely’ or ‘commonly’, and those that combined a prob-
ability statement with a text description (15/31, 48%)
such as ‘very rarely (< 1 in 1000)’.
Severity of adverse effects
Over half of the study documents do not include any
information about the severity of potential adverse
Table 2 Length of documents describing adverse effects and risk
Minimum and
maximum (words)
Median
(words)
Mean
(words)
% of overall
mean (words)
1st QR 3rd QR IQR
Musculoskeletal 27–236 105 157 5.4 48 291 242
Mental and behaviour disorders 0–529 336 304 9.2 221 364 143
Cancer 127–1165 559 616 11.5 472 643 171
All clinical areas 0–1165 326 354 10.4 127 516 389
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effects (18/33, 55%). Where the severity of adverse ef-
fects are stated, it is described as either ‘mild’ (2/15,
13%); ‘serious’, ‘severe’ or ‘major’ (8/15, 53%); ‘life-threat-
ening’ or ‘fatal’ (2/15, 13%); or a combination of these.
Action to be taken by the participant in the event of
adverse effects
Many of the study documents (14/33, 42%) did not con-
tain information about what that action the participant
should take in the event of an adverse effect occurring.
Of those that did, the majority informed the participant
that they should contact the study team or doctor or re-
port at the next study visit (12/19, 63%), and/or contact
another clinician such as their GP or the nearest A&E
department (9/19, 47%). In a small number, the informa-
tion was contained in a separate information leaflet
given to the participant (2/19, 11%), the content of
which was not included in this study.
Description of the potential beneficial effects of the
intervention
A third of the study documents (10/33, 30%) did not
refer to any potential benefits from the study interven-
tion. One stated that there would be no benefits for par-
ticipants receiving the placebo beyond those of the
weekly cancer treatment that would be the same outside
of the trial [ID 107]. Others expressed hope that the par-
ticipant would derive some benefit, whilst emphasising
that any benefits were unknown or uncertain. Of these,
most (11/33, 33%) reported a specific potential benefit
such as delaying the time to progression of your disease
or helping them to feel stronger or experience a reduc-
tion in pain. Four described the potential benefits from
the intervention in general or non-specific terms such as
‘the medicine may help you and your cancer’.
Description of the potential beneficial effects of the study
The majority of the documents (24/33, 73%) included a
statement about the study benifiting future patients or
that information from the study will increase under-
standing about the condition and which treatments are
effective, even if the participant does not benefit directly.
An additional two stated that some people find it re-
warding to take part in medical research. Some of the
documents (8/33, 24%) reported that participants may
find the additional contact with the research or clinical
team reassuring or helpful, or that there may be benefits
from the additional monitoring that forms part of the
study schedule, or that the study assessments could re-
sult in finding a previously unknown condition. Four of
the documents stated that there may be benefits from
the additional blood tests or scans performed as part of
the study. Three documents stated the benefits of receiv-
ing an intervention that is not routinely offered by the
NHS and so is unavailable outside of the study, or that it
was provided free of charge (a vaccination). Two studies
described the potential benefits that participants might
gain from understanding their condition better through
the use of particular study measures. Five explicitly
stated that the participant will not benefit from taking
part in the study, and three did not include any state-
ment about any potential benefits.
Relative position of beneficial and adverse effects
Adverse effects were usually presented before beneficial
effects (21/33, 64%). Most commonly, the potential ad-
verse effects and beneficial effects were directly adjacent
to each other (19/33, 58%), less often the sections were
presented apart by either one page (5/33, 15%) or 2+
pages (4/33, 12%), or dispersed in several locations such
as brief details in the introduction with additional infor-
mation later in the document (2/33, 6%). One document
had a detailed description of the potential adverse effects
(and the likelihood of each side effect) in a table in an
appendix [ID 220], and one had no description of the
potential benefits or adverse effects [ID 210].
Discussion
Summary of findings
Complex language decreases readability and negatively
impacts on the informed consent process [19]. Commu-
nication and a lack of clear information play a key role
in nocebo effects, and factors relating to information
delivery and framing processes can potentially act on a
patient’s outcome expectancies that could adversely
impact not only treatment effectiveness but also the inci-
dence of side effects [20].
In our sample of PILs, we found that the level of read-
ability is difficult overall. In spite of HRA guidance stat-
ing that PILs should be written in non-technical terms
that a layperson will understand, most PILs in our ana-
lysis required an A level education to understand them.
Our main finding was heterogeneity of the way in
which adverse events were presented in PILs. A third of
the PILs reported intervention benefits. The style used
to present adverse events also varied from single
sentences to long bulletpoint lists. However, many PILs
are not written from scratch and are often derived from
previous information sheets. Other trials may use the
HRA template or a Sponsor required template. This is
likely to explain the heterogeneity of the presentation.
Informed consent processes may induce nocebo
effects, and information framing is known to impact on
side effect expectation in clinical practice [21]. There
have previously been calls for information about benefits
and side effects to be contextualised and for side effect
information to be presented in a positively framed way
[21]. In this study, adverse events were usually (but not
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always) presented before benefits and the severity of ad-
verse events was rarely discussed. Whilst the length of
the text and the order in which the relevant sections
were presented cannot be said to be directly associated
with nocebo effects, it will impact on how the informa-
tion about the potential harms and benefits of the inter-
vention is framed to participants. The heterogeneity and
complexity of language in PILs suggest that the framing
effects of how the information was being provided were
largely unconsidered.
Strengths and limitations
A strength of this study is that it is the first study that
has explored how potential side effects in trials are pre-
sented in written information to participants. Another
strength is that we have analysed the readability of the
PILs in order to explore how readable PILs are overall
across multiple disciplines but also, how understandable
the adverse effects that are described are to participants.
A limitation of this study is the small numbers of in-
formation leaflets that we were able to analyse, and they
were drawn from a single database. Initially, 65 studies
were considered to be part of this research and only 34
PILs were available for analysis. Whilst this is a limita-
tion of our research, it also highlights that PILs are not
as publicly accessible as they potentially could be, espe-
cially for studies that are funded by public funders such
as the National Institute for Health Research (NIHR).
The ISCRTN website contains a section for accessing
PILs; however, our research found that it is rare that
they are uploaded to the website. We were only able to
extract 2 PILS directly from the ISCRTN website.
Implications for future research
Our analysis suggests that future PILs should follow
guidance on readability (generally, by making them more
easily understood). Exploring participant’s perceptions of
the information provided to them in the PILs is import-
ant to explore so see how they are affected by the con-
tent and the presentation of the information and the
impact of information framing on nocebo effects. Previ-
ous research has highlighted the importance of develop-
ing participant materials in partnership with patients
and other user groups [22]. In addition, feedback from
participants who have used these PILs around the
nocebo effects would be invaluable to the design of
future PILs.
Further research should also focus on exploring how
future PILs can be developed which take account of
decision-making theories and frameworks which suggest
that weighing up the potential risks and benefits of a
situation is a key component of decision-making [23].
Conclusions
Communication of the potential harms and benefits of
participating in a trial are important elements of in-
formed consent, and how the relative harms and benefits
are framed in participant information materials will im-
pact on participant understanding. Current PILs have
low readability and may present information about trial
harms that induces nocebo effects. Future research
should investigate ways to standardise the information
about trial harms so that it is understandable to the lay
public and does not induce unnecessary nocebo effects.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04591-w.
Additional file 1.
Abbreviations
GCP: Good clinical practice; IMP: Investigational medicinal product; ISRC
TN: International Standard Randomised Controlled Trials Number;
PILs: Participant information leaflets
Acknowledgements
The authors would like to thank all of the trials who sent their participant
information leaflets to be included as part of this study.
Authors’ contributions
KH and VS developed the idea. NK, VS and SB participated in data extraction.
VS completed the qualitative analysis and NK completed the quantitative
analysis. JH checked a sample of the data extraction sheets and edited all
versions of the manuscript. NK wrote the first draft and drafted the final
manuscript. KH provided editorial advice and edited all versions of the
manuscript. All authors read and approved the final manuscript.
Funding
This project did not have any external funding.
Availability of data and materials
All data are available as a supplementary material.
Ethics approval and consent to participate
This was a review of ethically approved patient information leaflets. Consent
was not required.
Consent for publication
The corresponding and all other authors give consent to Trials to publish
this manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1Centre for Trials Research, Cardiff University, Neuadd Meirionnydd, Heath
Park, Cardiff CF14 4YS, UK. 2Nuffield Department of Primary Care Health
Sciences, University of Oxford, Radcliffe Primary Care Building, Oxford OX2
6GG, UK. 3Department of Oncology, University of Oxford, Old Road Campus
Research Building Roosevelt Drive, Headington, Oxford OX3 7DQ, UK.
Received: 29 January 2020 Accepted: 7 July 2020
References
1. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo
effect: recent advances and current thought. Annu Rev Psychol. 2008;59:
565–90.
Kirby et al. Trials          (2020) 21:658 Page 7 of 8
2. Fortunato JT, Wasserman JA, Londyn Menkes D. When respecting
autonomy is harmful: a clinically useful approach to the nocebo effect. Am
J Bioethics. 2017;17(6):36–42. https://doi.org/10.1080/15265161.2017.
1314042.
3. Howick J, Webster R, Kirby N, et al. Rapid overview of systematic reviews of
nocebo effects reported by patients taking placebos in clinical trials. Trials.
2018;19:674. https://doi.org/10.1186/s13063-018-3042-4.
4. Mitsikostas DD, et al. Nocebo is the enemy, not placebo. A meta-analysis of
reported side effects after placebo treatment in headaches. Cephalalgia.
2011;31(5) http://journals.sagepub.com/doi/abs/10.1177/0333102410391485.
5. Mitsikostas DD, et al. Nocebo in clinical trials for depression: a meta-analysis.
Psychiatry Res. 2013;215(1) https://www.psy-journal.com/article/S0165-1781
(13)00670-7/abstract?code=psy-site.
6. Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating
nocebo effects in neuropathic pain trials. J Neurol. 2012;259(3):436–47.
https://doi.org/10.1007/s00415-011-6197-4.
7. Stathis P, et al. Nocebo as a potential confounding factor in clinical trials for
Parkinson's disease treatment: a meta-analysis. Eur J Neurol. 2012; https://
onlinelibrary.wiley.com/doi/full/10.1111/ene.12014.
8. Mitsikostas DD, et al. Nocebo in fibromyalgia: meta-analysis of placebo-
controlled clinical trials and implications for practice. Eur J Neurol. 2011;
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1468-1331.2011.03528.x.
9. Golomb B. When are medication side effects due to the nocebo
phenomenon? JAMA. 2002;287(19):2502–4.
10. Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful unraveling
the mechanisms of the nocebo effect. Neuroscience. 2007;147(2):260–71.
11. HRA Consent and Participant Information Guidance v6 Sept 2018 http://
www.hra-decisiontools.org.uk/consent/whatsnew.html. Accessed 1 Feb
2019.
12. Guideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995.
https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-6-r2-
guideline-good-clinical-practice-step-5_en.pdf. Accessed 1 Dec 2016.
13. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 7th ed. Oxford:
Oxford University Press; 2013.
14. Myers MG, Cairns JA, Singer J. The consent form as a possible cause of side
effects. Clin Pharmacol Ther. 1987;42(3):250–3. https://doi.org/10.1038/clpt.
1987.142.
15. Grady C. Payment of clinical research subjects. J Clin Invest. 2005;115(7):
1681–7. https://doi.org/10.1172/JCI25694.
16. Automated Readability Index – readability formulas www.
readabilityformulas.com–. Accessed 6 Jan 2019.
17. Bengtsson M. How to plan and perform a qualitative study using content
analysis. NursingPlus Open. 2016;2:8–14.
18. Shepherd V, Wood F, Griffith R, Sheehan M, Hood K. Research involving
adults lacking capacity to consent: a content analysis of participant
information sheets for consultees and legal representatives in England and
Wales. Trials. 2019;20:233. https://doi.org/10.1186/s13063-019-3340-5.
19. Taylor HE, Bramley DE. An analysis of the readability of patient information
and consent forms used in research studies in anaesthesia in Australia and
New Zealand. Anaesth Intensive Care. 2012;40(6):995–8. https://doi.org/10.
1177/0310057X1204000610.
20. Klinger R, Blasini M, Schmitz J, Colloca L. Nocebo effects in clinical studies:
hints for pain therapy. Pain Rep. 2017;2(2):e586. https://doi.org/10.1097/PR9.
0000000000000586.
21. Heisig SR, Shedden-Mora MC, Hidalgo P, Nestoriuc Y. Framing and
personalizing informed consent to prevent negative expectations: an
experimental pilot study. Health Psychol. 2015;34(10):1033–7.
22. Innes K, Cotton S, Campbell MK, Elliott J, Gillies K. Relative importance of
informational items in participant information leaflets for trials: a Q-
methodology approach. BMJ Open. 2018;8(9):e023303. https://doi.org/10.
1136/bmjopen-2018-023303.
23. Durand MA, Stiel M, Boivin J, Elwyn G. Where is the theory? Evaluating the
theoretical frameworks described in decision support technologies. Patient
Educ Couns. 2008;71(1):125–35. https://doi.org/10.1016/j.pec.2007.12.004.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kirby et al. Trials          (2020) 21:658 Page 8 of 8
